Trial · NCT03990571
Adverse events128
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 128
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Axitinib, Avelumab) | 2 | 34 | 2 |
| other | Alanine aminotransferase increased | Investigations | Treatment (Axitinib, Avelumab) | 5 | 34 | 8 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Axitinib, Avelumab) | 2 | 34 | 3 |
| other | Allergic reaction | Investigations | Treatment (Axitinib, Avelumab) | 2 | 34 | 2 |
| other | Anemia | Investigations | Treatment (Axitinib, Avelumab) | 4 | 34 | 6 |
| other | Anorexia | Investigations | Treatment (Axitinib, Avelumab) | 7 | 34 | 8 |
| other | Anxiety | Investigations | Treatment (Axitinib, Avelumab) | 1 | 34 | 1 |
| other | Arthralgia | Investigations | Treatment (Axitinib, Avelumab) | 1 | 34 | 1 |
| other | Arthritis | Musculoskeletal and connective tissue disorders | Treatment (Axitinib, Avelumab) | 1 | 34 | 2 |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Axitinib, Avelumab) | 5 | 34 | 5 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (Axitinib, Avelumab) | 3 | 34 | 3 |
| other | Blurred vision | Eye disorders | Treatment (Axitinib, Avelumab) | 2 | 34 | 2 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Treatment (Axitinib, Avelumab) | 1 | 34 | 1 |
| other | Chest pain - cardiac | Cardiac disorders | Treatment (Axitinib, Avelumab) | 3 | 34 | 3 |
| other | Chest wall pain | Musculoskeletal and connective tissue disorders | Treatment (Axitinib, Avelumab) | 1 | 34 | 1 |
| other | Constipation | Gastrointestinal disorders | Treatment (Axitinib, Avelumab) | 7 | 34 | 8 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Axitinib, Avelumab) | 7 | 34 | 7 |
| other | Creatinine increased | Investigations | Treatment (Axitinib, Avelumab) | 3 | 34 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Axitinib, Avelumab) | 12 | 34 | 21 |
| other | Dizziness | Nervous system disorders | Treatment (Axitinib, Avelumab) | 1 | 34 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03990571/events